Veeva Systems Inc.
NYSE:VEEVMedical - Healthcare Information Services
-$2.83 today
- Market cap
- $44.88B
- Beta
- 0.95
- P/E (TTM)
- 26.4
- EPS (TTM)
- $5.76
Volume 2.74M
Average 3.01M
VEEV Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Veeva Systems Inc.NYSE: VEEV
Research & Development · Q2 FY2027 · quarter ended Jul 2026
Research & development growth accelerates
Q2 FY2027 research & development of $222.92M rose 15.7% year over year, ahead of the +12.5% change in trailing-twelve-month research & development. Sequentially, it rose 7.0% from the prior quarter. Over 3 fiscal years it compounded at +13.8% a year.
Context
- Research & development amounted to 24.0% of revenue in FY2026, down 1.2 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +15.7% holds above the trailing-twelve-month pace of +12.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2026
- 767.39M USD
- Year-over-year change
- +10.7%
- 4-year CAGR
- +19.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2026 | 2026-01-31 | 767.39M | +10.7% |
| FY2025 | 2025-01-31 | 693.08M | +10.2% |
| FY2024 | 2024-01-31 | 629.03M | +20.9% |
| FY2023 | 2023-01-31 | 520.28M | +36.2% |
| FY2022 | 2022-01-31 | 382.04M | — |
Research & Development vs competitors
How VEEV compares with its peers on the latest reported figures
- VEEV's LTM Jul 2026 research & development of $821.92M is the highest of the 5 companies compared; the peer median is $103.34M.
- Its year-over-year change of +12.5% is the 2nd highest of 4, against a peer median of +7.4%.
- Research & development amounts to 23.8% of revenue for VEEV, versus a peer median of 20.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $821.92M | +12.5% | +13.8% | 23.8% | |
| LTM Sep 2026 | $160.31M | -11.5% | +11.1% | 59.6% | |
| LTM Sep 2026 | $154.14M | +47.9% | +17.7% | 23.3% | |
| LTM Mar 2026 | $52.54M | +7.4% | +4.8% | 16.9% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding VEEV) | $103.34M | +7.4% | +11.1% | 20.1% | |
Competitors are the stored peer set for VEEV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jan 2022 | FY2023 Jan 2023 | FY2024 Jan 2024 | FY2025 Jan 2025 | FY2026 Jan 2026 |
|---|---|---|---|---|---|
| Revenue | 1.85B | 2.16B | 2.36B | 2.75B | 3.2B |
| Cost of Revenue | 503.68M | 609.41M | 677.29M | 699.64M | 782.02M |
| Gross Profit | 1.35B | 1.55B | 1.69B | 2.05B | 2.41B |
| Gross Margin | 72.8% | 71.7% | 71.3% | 74.5% | 75.5% |
| Research & Development | 382.04M | 520.28M | 629.03M | 693.08M | 767.39M |
| Selling, General & Admin | 459.57M | 566.29M | 628.02M | 662.47M | 729.54M |
| Operating Expenses | 841.6M | 1.09B | 1.26B | 1.36B | 1.5B |
| Depreciation & Amortization | 27.45M | 29.12M | 32.63M | 39.38M | 50.47M |
| EBITDA | 539.76M | 538.22M | 620.65M | 958.76M | 1.24B |
| EBITDA Margin | 29.2% | 25.0% | 26.3% | 34.9% | 39.0% |
| Operating Income | 505.5M | 459.09M | 429.33M | 691.44M | 916.37M |
| Operating Margin | 27.3% | 21.3% | 18.2% | 25.2% | 28.7% |
| Interest Income | 14.73M | 45.86M | 133.75M | 207.99M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 6.82M | 50.01M | 158.69M | 227.95M | 278.14M |
| Income Before Tax | 512.31M | 509.1M | 588.02M | 919.38M | 1.19B |
| Pre-Tax Margin | 27.7% | 23.6% | 24.9% | 33.5% | 37.4% |
| Income Tax Expense | 84.92M | 21.39M | 62.32M | 205.24M | 285.6M |
| Net Income | 427.39M | 487.71M | 525.71M | 714.14M | 908.91M |
| Net Margin | 23.1% | 22.6% | 22.2% | 26.0% | 28.4% |
| EPS (Basic) | 2.79 | 3.14 | 3.27 | 4.41 | 5.55 |
| EPS (Diluted) | 2.63 | 3.00 | 3.22 | 4.32 | 5.44 |
| Weighted Avg Shares | 153.25M | 155.39M | 160.53M | 161.88M | 163.67M |
| Weighted Avg Shares (Diluted) | 162.28M | 162.44M | 163.49M | 165.23M | 167M |
Veeva Systems Inc.
NYSE:VEEV
Intrinsic Alpha fair value
Locked
Current Price
$277.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.